Navigation Links
Sloning and the Kornberg group at Stanford University starting evaluation project regarding the synthesis of a Statistically Randomized Gene Library
Date:4/24/2008

Munich, Germany, April 24, 2008 / b3c newswire / - Sloning BioTechnology and Roger Kornberg’s group at Stanford University are working on a project to synthesize a gene mutant library where selected codons are introduced in a statistically expected and controlled ratio at preselected positions within a given DNA sequence.

Sloning will utilize its core technology, Slonomics™, a unique DNA engineering platform using defined sets of double stranded DNA triplets to generate this highly sophisticated kind of gene mutant library. 

The group of Dr. Roger Kornberg (Nobel Prize Laureate in Chemistry 2006) at Stanford University will perform in vivo screens based on the library provided by Sloning to identify relevant mutants of a S. cerevisiae RNA Polymerase II.

Jan Van den Brulle, Scientific Director at Sloning commented, “We are looking forward to work together with Dr. Kornberg’s group. This project gives us again the opportunity to demonstrate the power of our technology”.

Dr. Kornberg stated, "this mutant library will allow us to dissect and better understand the transcription mechanism."  


About Sloning - www.sloning.com


Located in Munich, Germany, Sloning is a private company with the number one technology for the synthesis of diverse genetic libraries. Diverse genetic libraries are essential in the screening for new and improved therapeutic proteins or proteins used in technical applications. Sloning uses Slonomics™ to synthesize customised mutant libraries for its customers from the biopharmaceutical, industrial biotech, agribiotech and food industries worldwide. In particular, Sloning takes an ethical approach to synthetic biology and is a founder member of the Industry Association of Synthetic Biology formulating industry standards for biosafety and biosecurity.


Contact

Dr. Jan Van den Brulle, Scientific Director +49 89 80 95 – 0 email: j.vandenbrulle@sloning.de
'/>"/>
b3c newswire

Related biology technology :

1. Avicena Group to Present at Noble Financial Conference
2. Chrome Group to Seek Listing for Some of its Subsidiaries
3. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
4. Reed Group to Provide MDA Internet Disability Duration Guidelines to U.S. Navy
5. SportCoatings; The North American Booster Club Association (NABCA); the Coatings Specialist Group New Booster Program Goes High Tech With Invisible Antimicrobial Defense
6. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
7. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Completion of $2,277,000 Equity Financing
8. ThirdBiotech Networking Group Launches
9. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Appointment of Mark C. Mirken as its President and Chief Operating Officer
10. Reed Group Ltd. Announces Enterprise License for New Zealands Accident Compensation Corporation
11. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
Breaking Biology News(10 mins):